Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. develops carbohydrate-based biotechnology programs focused on hypoxia, viral diseases, inflammation, metabolic health, and degenerative disease. News about BIXT commonly centers on ProLectin-M, its investigational oral antiviral candidate, including clinical study results, dose-optimization work, viral-clearance data, and regulatory-discussion updates for later-stage development.
Company updates also cover Bioxytran’s galectin-targeting platform, research collaborations involving polysaccharide and oligosaccharide interactions, and applications such as PHM23 in avian influenza research. Commercial news includes A-SUQAR®, a chewable dietary supplement containing a proprietary partially hydrolyzed guar gum formulation, along with distribution agreements and private-placement financing used for working capital and development programs.
Bioxytran (OTCQB: BIXT) reported initial clinical observations from the first Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient treated with PLICID, an investigational galectin antagonist designed using its Artificial Super Intelligence (ASI) carbohydrate drug design platform. The patient received once-weekly intravenous PLICID injections and was reported to regain finger function and the ability to walk several miles, with no adverse events reported during treatment. According to Bioxytran, this single-patient experience supports further evaluation of PLICID in a larger, appropriately designed clinical study. PLICID targets galectins, proteins implicated in inflammatory, fibrotic, malignant, and neurological diseases, via complex carbohydrate structures generated from NMR spectroscopy data. The company is advancing a pipeline of ASI-designed galectin antagonists across multiple indications, including CIDP and other degenerative and inflammatory conditions.
Bioxytran (OTCQB:BIXT) has executed a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry to advance ASI-driven design of novel polysaccharide and oligosaccharide drugs. The program, led by Dr. Kevin Mayo, will use advanced NMR spectroscopy to study carbohydrate interactions with biologically relevant targets.
The company is applying its Artificial Super Intelligence platform across three areas: broad-spectrum oral antivirals, cancer metastasis research, and oxygenation therapy for stroke. According to Bioxytran, the ASI system interprets NMR data to design complex carbohydrate antagonists against galectin-related targets in viral and malignant diseases, including Galectin-3 in metastasis.
Bioxytran’s lead oral galectin antagonist, ProLectin-M, showed in Phase 2 randomized, double-blind, placebo-controlled trials that 100% of treated patients achieved viral load below assay detection by Day 7, with 88.9% at Day 5 on the highest dose versus 20% for placebo and no viral rebounds over 14 days.
Bioxytran (OTCQB:BIXT) announced the publication of a sponsored corporate research report by Globe Small Cap Research on July 29, 2026. The report frames Bioxytran as a multi-platform biotechnology company focused on carbohydrate science, galectin antagonism, and oxygen-transport therapeutics, spanning antiviral candidates, stroke and hypoxia programs, and the A-SUQAR dietary supplement.
According to the report, key developments include positive Phase 2 data for ProLectin-M in a 38-patient randomized, double-blind, placebo-controlled antiviral trial, a proposed 408-patient outpatient study that may serve as a potential registrational pathway, an A-SUQAR commercial distribution agreement, ongoing work on the BXT-25 oxygen-transport platform, and a March 2026 private placement raising about $1.2 million. The report highlights insider ownership above 50%, notes the need for additional capital, and describes BIXT as a high-risk small-cap with multiple potential avenues for progress.
Bioxytran (OTCQB:BIXT) highlighted a new book by physiologist Avraham Mayevsky on real-time brain tissue oxygenation, which uses FDA-cleared monitoring technology licensed exclusively to Bioxytran. The work focuses on cerebral ischemia, hypoxia, epilepsy, traumatic brain injury, and related conditions in rat models.
According to Bioxytran, the physiological mapping methods and advanced monitoring tools described may inform future evaluation, study design, and indication selection for its investigational oxygen diffusion therapeutic BXT-25, being developed for immediate stroke treatment and other hypoxia-related conditions.
Bioxytran (OTC: BIXT) completed a private placement on March 18, 2026, raising approximately $1.2 million. The company issued about 21,071,667 common shares at ~$0.055 per share and warrants to buy up to 19,750,001 shares at $0.12, five-year term.
The company said it will use net proceeds for working capital, development programs, and selected commercialization, including an A-SUQAR® dietary supplement launch expected this quarter.
Bioxytran (OTCQB: BIXT) reported positive dose optimization for ProLectin-M and outlined plans toward a Phase 3 registrational trial. A 39-participant study identified a 16,800 mg/day regimen achieving 90% viral clearance by Day 5 with a favorable safety profile. The company is in discussions with the FDA and India’s CDSCO and proposes a ~408‑participant randomized, placebo-controlled outpatient Phase 3 trial for standard‑risk patients with mild‑to‑moderate COVID-19 and other viral infections.
Bioxytran also reported in vitro activity versus RSV and H1N1, a University of Georgia collaboration on H5N1 research, and advancement of an IV formulation for Long COVID.
Bioxytran (OTCQB:BIXT) reported Phase 1b/2a results for oral ProLectin-M in mild‑to‑moderate COVID‑19 on March 2, 2026. The highest dose (16,800 mg/day) produced statistically significant earlier viral clearance and faster clinical improvement by Day 5 versus placebo (p=0.001), with no serious adverse events reported.
Study enrolled 39 participants across four arms; by Day 7 viral clearance occurred across all arms, consistent with expected natural recovery. Company plans further larger studies to evaluate ProLectin-M's galectin‑targeting mechanism and oral therapeutic potential.
Bioxytran (OTCQB:BIXT) initiated a research collaboration with the University of Georgia on February 23, 2026 to evaluate its lead candidate PHM23 against Highly Pathogenic Avian Influenza H5N1.
The program follows an NDA from March 2025 and was included in UGA's submission to the USDA's $100M HPAI Poultry Innovation Grand Challenge. In vitro data versus viruses similar to H5N1 support further study.
Bioxytran (OTCQB:BIXT) announced a commercial Distribution Agreement with Khoury Medical LTD to commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG), in permitted markets.
The agreement preserves Bioxytran's pharmaceutical rights, uses OEM manufacturing, and offers potential volume-based marketplace exclusivity subject to purchase thresholds and conditions.
Bioxytran (OTCQB: BIXT) reported positive Phase 2 results for orally administered ProLectin-M in 38 subjects with acute viral infection. The trial showed 100% viral RNA non-detection by Day 7 (p=0.001), no viral rebounds during a 14-day post-treatment observation, and informed a four-tablet-per-day dose selection for late-stage development.